2011 Rna Course Part 1

Molecular Pathology of pre-mRNA splicing Part 1

International Centre for Genetic Engineering and Biotechnology. Trieste (Italy)

3’ 5’ 3’ 5’ 3’ 5’3’ 5’ 3’ 5’

AAAAAAAAAA

aug uag

Transcription

5’UTR

ORF

3’UTR

AAAAAAAAAA

pre-mRNA splicing:

Poly-A5’cap

PolII PolII PolII

PolII

Splicing

Export and Translation

DNA

pre-mRNA

mRNA

protein

aug uag

Local RNA secondary structure can change the way these sequences are displayed

Basic recognition levels are determined by trans-acting factor(s) binding to consensus splicing regulatory sequences

Internal exonic or nearby intronic regions (Splicing Regulatory Elements, SREs) can regulate these basic factors by attracting both negative and positive trans-acting factors

-External stimuli/cellular stress

-Spliceosomal rearrangements due to processing of upstream introns/exons

-RNA Pol II Kinetics and Processivity

-Variability of alternative splicing events in upstream exons

3’ss 5’ss

BP

SREs

Fig.1

Com

bin

ator

ial e

ffec

t of

sp

lici

ng

regu

lato

ry f

acto

rs in

exo

n in

clu

sion

/sk

ipp

ing

dec

isio

ns

Inclusion

Skipping

Disease-causing mutations can occur in all these types splicing controlling elements:Disease-causing mutations can occur in all these types splicing controlling elements:

Splicing mutations can be found in virtually any intron-containing gene. The frequency depends on overall length and individual susceptibilities

Baralle D. et al. EMBO Rep 2009; 10:810-816.

What happens when one of the basic elements is altered?

ATM

CFTR

Herg

NF-1

CFTR

GBA

Summary of “wet” splicing methodologies to identify pathological splicing mutations:

Baralle D. et al. EMBO Rep 2009; 10:810-816.

Direct mRNA amplification from patients

Marfan syndrome (MFS; MIM154700) is a relatively common autosomal dominant hereditary disorder of connective tissue with prominent manifestations in the skeletal, ocular, and cardiovascular systems.

13% of reported mutations consist of various classes of splicing errors, most commonly affecting canonical splice sequences at exon/intron boundaries

1kb plus e12F/e14R, 239bp, exon13-1510T>C & exon14-1633C>Te15F/e17R, 196bp, exon16-1883G>A, -1909T>C, -1916G>Ae19F/e21R, 173bp, exon19-2293G>A & exon20-2328T>Ae20F/e24R, 465bp, exon22-2645C>Te24F/e25R, 180bp, exon-25-2927G>Ae26F/e30R, 504bp, exon27-3332G>A, exon28-3422C>T, exon29-3533A>Ge32F/x35R, 532bp, exon33-4069G>A, exon34-4096G>Ae44F/e48R, 474bp, exon46-5627G>A & -5789A>Ge51F/e53R, 224bp, exon51-6251G>Ce54F/e57R, 357bp, exon55-6694T>C, exon56-6815A>Ge60F/e63R, 363bp, exon60-7379A>G, exon62-7606G>A, -7633C>T, -7664G>Te63F/e65R, 402bp, exon64-7916A>GBlank1kb plus

Development of RT-PCRs for detecting RNA splicing in the FBN1 gene

Covering 24 UVs in 19 exons

In collaboration with EURASNET (and in this case with Dr. Diana Baralle:

Detection a RNA splicing mutation in FBN1 exons 60 & 62, by RT-PCR

RT-PCR was performed on patients’ peripheral blood samples. The PCR primers are located in exon60 and exon63 to give a 363bp product. It covers 4 UVs in 2 exons: c.7606G>A in exon 60, and 3 UVs at c.7664G>T, c.7633C>T and c.7379A>G in exon 62. An extra PCR band was detected in lane 2 for patient with c.7606G>A.

1 2 3 4 5 6 7

Lane 1: marker; Lane 2: c.7606G>A; e60Lane 3: c.7664G>T; e62Lane 4: c.7633C>T; e62Lane 5: c.7379A>G; e62Lane 6: normal buffy coat;Lane 7: PCR blank

Minigenes and exon skipping in Neurofibromatosis

Hybrid minigenes transfection in different cell

types 0.5 μg DNA

300.000 cells

24 hours

RT-PCR analysis of splicing products

using specific oligonucleotides

Our “in house” minigene system:

-globin gene promoter andSV40 enhancer sequences

polyA site derived fromthe -globin gene

fibronectin exons

-globinexons

Ophthalmologic

• Optic pathway tumor

• Lisch nodules

• Glaucoma (rare)

Musculoskeletal

• Speniod wing dysplasia (5-10%)

• Long bone narrowing (2-5%)

• Scoliosis (20-30%)

• Short stature (25-35%)

• Relative Macrocephaly

Cardiovascular

• Hypertension (2-5%)

• Congenital heart defect (2%)

Tumours

Neurological

• Hydrocephalus (5%)

• Seizures (6-7%)

• Educational difficulty (40-60%)

• Sensorineural hearing loss (5%)

• Precocious puberty (2-5%)

Ricardi 1992, Huson and Hughes 1994, Friedman and Birch 1997.

NF-1 symptoms:

In NF-1 exon 37 a practical example of overlap between a coding and splicing mutation is represented by the C6792G mutation that for a long time was thought to be a translational mutation.

Baralle et al. FEBS Lett. 2006 580: 4449-4456.

Using as a reference the results obtained from a patient’s lymphoblasts carrying the C6792G mutation we have investigated the importance of genomic context on reproducing the effects of splicing of this mutation:

Baralle et al. FEBS Lett. 2006 580: 4449-4456.

Buratti et al. NAR 2006 34: 3494-3510.Baralle et al. FEBS Lett. 2006 580: 4449-4456.

The importance of genomic context:

Long QT Syndrome and intron retention

• KCNQ1 (KVLQT1, LQT1)• KCNH2 (HERG, LQT2)• KCNE1 (mink, LQT5)• KCNE2 (MiRP1, LQT6)• SCN5A (LQT3)

Potassium channel subunits

Cardiac sodium channel gene

Normal QT (390-410 msec) Prolonged QT (> 440 msec)

Genes involved in Long QT syndrome:

The long QT syndrome (LQTS) is a heart condition associated with prolongation of repolarisation (recovery) following depolarisation (excitation) of the cardiac ventricles. It is associated with fainting and sudden death. Hereditary long QT syndrome (LQTS) is caused by over 250 mutations in five genes

We have studied a patient that presented an IVS7+6T>C mutation in the HERG gene.

One of the most important events in 5’ splice site definition is represented by base pairing of the U1snRNA component of U1snRNP with the 5’ splice site consensus sequence.

A “T” in the +5 position is rather loosely conserved:

C A G G U R A G U Zhang et al., 1998

Is a +6T>C change capable of affecting splicing?

NdeI

NdeI

Exon 7 Wt CTCATTGGCT/gtgagtgtcExon 7 +6T>C CTCATTGGCT/gtgagcgtc

Exon 7

HERG ex 7 W

t

HERG ex 7

+6T>C

HERG ex 7 +6T>C

+ U1 C>G

Zhang et al., 2004. J Am Coll Cardiol; 44(6):1283-91

200

400500650

1650

8501000

HERG

The +6T>C is a mutation perturbs U1 snRNP interaction with the 5’ss and in a minigene system causes intron retention.

RNA secondary structure, pre-mRNA splicing, and disease

m7GpppG

“cap”

AAAAAm7GpppG

“polyA”

AAAAA

“polyA”

In theory, mRNA molecules should be anything but linear:

However, with the exception of the 3’UTR and 5’UTR regions of mRNAs which are sometimes known to fold in characteristic secondary structures the evidence gathered from many splicing systems suggests that secondary structure seldom needs to be invoked as a regulator of splicing.

“cap”

The notion that mRNA molecules may behave largely as linear molecules is based on the observation that a nascent trascript is often coated by many different proteins (mainly belonging to the hnRNP proteins family) which keep it in a linear conformation

Gevertz et al. RNA 2005; 11: 853-863

Percent of sequences in each pool that fold to linear structures (represented by solid line), structures with one

branch (dashed line), and structures with two or more branches (dash-dotted line)

Four antibiotic-binding aptamer structures and their tree graphs

How easily does mRNA fold?.

The question still remains whether pre-mRNA molecules may retain some small structured “islands” and whether this structure can influence the splicing process.

Buratti and Baralle MCB 2004; 24: 10505-10514

Over the years experimental evidence has suggested that RNA folding can affect the presentation/distance of 5’ss, 3’ss, branch-point elements

Buratti and Baralle MCB 2004; 24: 10505-10514

………enhancer and silencer elements………..

Buratti and Baralle MCB 2004; 24: 10505-10514

……..by changing the overall architecture of the pre-mRNA…………

Buratti and Baralle MCB 2004; 24: 10505-10514

Varani, L et al. (1999) Proc. Natl. Acad. Sci. USA 96, 8229-8234

In the tau gene RNA secondary structure has been proposed to be responsible for the occurrence of fronto-temporal dementia and Parkinsonism.

Buratti and Baralle MCB 2004; 24: 10505-10514

Bioinformatics approaches

The bioinformatics connection:

Example of a program:

Schwartz et al., NAR, 2009, 37:W189-192

How good are bioinformatics programs?

How can RNA secondary structure be predicted?. Two main approaches are commonly used by researchers (both freely available on the web):

Energy minimization:

Probabilistic model + sequence comparison:

0

5

10

15

20

25

30

35

40

20 100 250 500 800

Random sequences can be generated at

Bioinformatics.org/sms/rand_dna.html

2. Average number of predicted secondary structures for random RNA sequence groups of differing length grows rapidly with length.

No.

of

stru

ctu

res

wit

hin

5%

sub

opti

mal

ity.

Sequence length (nucleotides)

Advantages and disadvantages of energy minimization approaches:

1. Fast, only requires the knowledge of the sequence of interest, is based on highly optimized energy minimization parameters and folding algorithms.

3. Prediction is highly dependent on the nucleotide “window” used for the analysis (changing the window by even a few nucleotides can profoundly change the output structure/energy).

catggcatcaaatcttttccccgtaccgactataggggcta catggcatcaaatcttttccccgtaccgactataggggcta

2. Requires the pre-requisite knowledge of many sequence that are already known to fold in a functionally-important structure. Any mistake in this choice can be fatal for the accuracy of the prediction.

Advantages and disadvantages of sequence-comparison approaches:

1. Allows to take into account evolutionary pressure to maintain a selected RNA structure (ie. evolution is doing the work instead of you), and as a result can provide the researcher with a single potential structure:

3. It is highly dependent on the correct “alignment” process between these sequences

Knudsen, B. et al. Nucl. Acids Res. 2003 31:3423-3428; doi:10.1093/nar/gkg614

Splicing therapy

A thalassemic allele of human -globin leads to production of a primary transcript that contains a cryptic exon, which is included in the majority of the -globin mRNAs. Antisense oligonucleotides (red arrows) can block the splice sites flanking the cryptic exon leading to a reduction in the inclusion of the cryptic exon. Similarly, antisense oligonucleotides can be used to reduce the ratio of exon 10+ to exon 10- MAPT transcripts. The inset shows the mechanism of action of a 5' splice site blocking antisense oligonucleotide that prevents U1 snRNP binding.

Garcia-Blanco et al. Nat.Biotechnol. (2004) 22:535-546.

Isoform-specific RNAi is presented in this panel. Exon-specific siRNAs (or micro RNAs) can be deployed to selectively destroy the mRNA encoding the anti-apoptotic Bcl-xL while not affecting the levels of the mRNA encoding the pro-apoptotic Bcl-xS.

Garcia-Blanco et al. Nat.Biotechnol. (2004) 22:535-546.

This schematic shows the paralogs SMN2 and a mutant allele of the more telomeric smn1. The regions spanning exons 6 through 8 of the primary transcripts are shown. The C to U difference in exon 7 of the two transcripts is indicated. This difference leads to skipping of exon 7 in a significant proportion of SMN2 transcripts. The schematic summarizes the use of IFNs, valproic acid and sodium butyrate to enhance transcription of SMN2. Enhancement of exon 7 inclusion by treatment with valproic acid, sodium butyrate and acalrubicin, perhaps mediated by increases in levels of SR proteins, is also indicated. Green arrows indicate demonstrated effects and dashed green arrows (or dashed red inhibitory lines) indicate weak or presumed effects.

Garcia-Blanco et al. Nat.Biotechnol. (2004) 22:535-546.

This schematic show variation of antisense oligonucleotides with the TOES and TOSS bifunctional reagent. One half of the therapeutic reagent targets it to the correct location within the primary transcript and the second component of the reagent provides either activating or silencing function. The inset provides schematics for the presumed mechanism of action.

Garcia-Blanco et al. Nat.Biotechnol. (2004) 22:535-546.

Varani, L. et al. NAR 2000 28:710-719

Surface representation with electrostatic potential map of the human tau exon 10 splicing regulatory element (left) and of its complex with neomycin B (right). Binding causes a marked increase in the stability of the regulatory wild type and mutant elements. This kind or results represent a starting point for the development of small compounds aimed at developing new splicing-based therapies.

Conclusions:

-Mutations affecting the pre-mRNA splicing process are a major cause of disease.

-Pathological splicing mutations that affect the exonic splicing code are difficult to predict owing to the great complexity of the pre-mRNA splicing process in higher eukaryotes.

-Presently, experimental analyses is still required to unambigously identify splicing-affecting mutations from harmless nucleotide variants.

-Splicing mutations associated with disease are not limited to exonic sequences.

-Better knowledge of splicing will offer new therapeutic opportunities to treat a great variety of diseases.